TransCode Therapeutics, Inc. (RNAZ)
Market Cap | 6.18M |
Revenue (ttm) | n/a |
Net Income (ttm) | -17.06M |
Shares Out | 6.57M |
EPS (ttm) | -229.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 103,999 |
Open | 0.955 |
Previous Close | 0.950 |
Day's Range | 0.936 - 0.990 |
52-Week Range | 0.420 - 128.000 |
Beta | 0.59 |
Analysts | Strong Buy |
Price Target | 3.00 (+219.15%) |
Earnings Date | Aug 12, 2024 |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA-... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for RNAZ stock is "Strong Buy" and the 12-month stock price forecast is $3.0.
News
![](https://cdn.snapi.dev/images/v1/s/e/press4-2470669.jpg)
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, to...
![](https://cdn.snapi.dev/images/v1/o/c/press6-2451673.jpg)
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new...
![](https://cdn.snapi.dev/images/v1/5/p/press3-2426903.jpg)
TransCode Therapeutics Open Letter to Shareholders
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholder, As y...
![](https://cdn.snapi.dev/images/v1/g/p/press9-2371447.jpg)
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today t...
![](https://cdn.snapi.dev/images/v1/6/g/press10-2354267.jpg)
TransCode Therapeutics Reports 2023 Results; Provides Business Update
BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported fi...
![](https://cdn.snapi.dev/images/v1/g/h/press14-2346082.jpg)
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today t...
![](https://cdn.snapi.dev/images/v1/h/q/press12-2317792.jpg)
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive...
![](https://cdn.snapi.dev/images/v1/r/3/conf10-2311865.jpg)
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced t...
![](https://cdn.snapi.dev/images/v1/v/t/press1-2283291.jpg)
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publicat...
![](https://cdn.snapi.dev/images/v1/m/o/press5-2254082.jpg)
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, to...
![](https://cdn.snapi.dev/images/v1/v/y/press19-2248631.jpg)
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...
![](https://cdn.snapi.dev/images/v1/5/w/press14-2239231.jpg)
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, tod...
![](https://cdn.snapi.dev/images/v1/p/z/press9-2235086.jpg)
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, tod...
![](https://cdn.snapi.dev/images/v1/c/v/press20-2228071.jpg)
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported fur...
![](https://cdn.snapi.dev/images/v1/t/m/press13-2225533.jpg)
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
![](https://cdn.snapi.dev/images/v1/1/j/press14-2216251.jpg)
TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives
BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (“TransCode” or the “Company”) (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA t...
![](https://cdn.snapi.dev/images/v1/u/2/press1-2192773.jpg)
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
![](https://cdn.snapi.dev/images/v1/k/t/conf3-2183754.jpg)
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present data ...
![](https://cdn.snapi.dev/images/v1/v/n/press7-2182663.jpg)
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, tod...
![](https://cdn.snapi.dev/images/v1/a/x/press3-2178689.jpg)
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, tod...
![](https://cdn.snapi.dev/images/v1/5/m/press4-2158123.jpg)
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported fin...
![](https://cdn.snapi.dev/images/v1/e/g/press11-2129075.jpg)
TransCode Therapeutics Withdraws Public Offering
BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, an...
![](https://cdn.snapi.dev/images/v1/n/o/press13-2125462.jpg)
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, to...
![](https://cdn.snapi.dev/images/v1/t/8/press5-2124246.jpg)
TransCode Therapeutics Announces Public Offering of Common Stock
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, to...
![](https://cdn.snapi.dev/images/v1/z/y/press5-2122433.jpg)
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced si...